Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) is projected to issue its quarterly earnings data before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.
Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) last posted its earnings results on Tuesday, March 25th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01. On average, analysts expect Atossa Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Atossa Therapeutics Stock Performance
Shares of Atossa Therapeutics stock traded down $0.05 during trading hours on Thursday, hitting $0.64. The company's stock had a trading volume of 836,048 shares, compared to its average volume of 954,003. The stock has a market cap of $82.99 million, a price-to-earnings ratio of -2.92 and a beta of 1.20. Atossa Therapeutics has a twelve month low of $0.63 and a twelve month high of $2.31. The firm has a fifty day moving average of $0.77 and a 200-day moving average of $1.08.
Wall Street Analyst Weigh In
ATOS has been the subject of a number of recent analyst reports. Ascendiant Capital Markets lifted their price target on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the company a "buy" rating in a research report on Monday, December 9th. HC Wainwright reaffirmed a "buy" rating and issued a $7.00 price objective on shares of Atossa Therapeutics in a research note on Wednesday, March 26th.
View Our Latest Analysis on Atossa Therapeutics
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Atossa Therapeutics stock. Bank of America Corp DE lifted its holdings in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) by 51.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 111,475 shares of the company's stock after acquiring an additional 37,809 shares during the period. Bank of America Corp DE owned 0.09% of Atossa Therapeutics worth $105,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 12.74% of the company's stock.
About Atossa Therapeutics
(
Get Free Report)
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
Read More
Before you consider Atossa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atossa Therapeutics wasn't on the list.
While Atossa Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
